Skip to main content
. 2013 Jul;15(7):694–711. doi: 10.1593/neo.13470

Figure 1.

Figure 1

GDC-0980 is efficacious in the HM-7 colorectal cancer xenograft model. (A) Mean tumor volumes from HM-7 tumor-bearing mice (n = 8) treated daily and p.o. with MCT vehicle (control) or GDC-0980 (10 mg/kg) for 7 days. B20.4.1.1 (10 mg/kg) was administered i.p. on days 1 and 7. Comparisons to control were performed using Dunnett's method; comparisons between treatment groups were performed using unpaired t test assuming unequal variances: **P < .01, ***P < .001. (B and C) HM-7 tumor-bearing mice (n = 4) were treated with a single oral dose of GDC-0980 (10 mg/kg) and harvested 1 hour post-dose to measure the levels of pAkt (S473) normalized to tAkt (B) or pS6RP (S235/236) normalized to tS6RP (C). *P < .05, **P < .01 compared to control using unpaired t test assuming unequal variances.